Apellis Pharmaceuticals Stock Today
| APLS Stock | USD 24.14 0.01 0.04% |
PerformanceVery Weak
| Odds Of DistressAverage
|
Apellis Pharmaceuticals is selling for under 24.14 as of the 22nd of March 2025; that is 0.04 percent decrease since the beginning of the trading day. The stock's lowest day price was 23.9. Apellis Pharmaceuticals has over 55 % chance of experiencing financial distress in the next 2 years of operation and has generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 22nd of December 2024 and ending today, the 22nd of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 9th of November 2017 | Category Healthcare | Classification Health Care |
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company has 125.52 M outstanding shares of which 17.34 M shares are presently shorted by private and institutional investors with about 13.02 trading days to cover. More on Apellis Pharmaceuticals
Moving together with Apellis Stock
Moving against Apellis Stock
Apellis Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Investor President | Meredith Kaya | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsApellis Pharmaceuticals can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Apellis Pharmaceuticals' financial leverage. It provides some insight into what part of Apellis Pharmaceuticals' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Apellis Pharmaceuticals (APLS) is traded on NASDAQ Exchange in USA. It is located in 100 Fifth Avenue, Waltham, MA, United States, 02451 and employs 705 people. Apellis Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 3.03 B. Apellis Pharmaceuticals conducts business under Biotechnology sector and is part of Health Care industry. The entity has 125.52 M outstanding shares of which 17.34 M shares are presently shorted by private and institutional investors with about 13.02 trading days to cover.
Apellis Pharmaceuticals currently holds about 852.8 M in cash with (87.87 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.76.
Check Apellis Pharmaceuticals Probability Of Bankruptcy
Ownership AllocationThe majority of Apellis Pharmaceuticals outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Apellis Pharmaceuticals to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Apellis Pharmaceuticals. Please pay attention to any change in the institutional holdings of Apellis Pharmaceuticals as this could imply that something significant has changed or is about to change at the company.
Check Apellis Ownership Details
Apellis Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Ubs Group Ag | 2024-12-31 | 2.6 M | |
| Fmr Inc | 2024-12-31 | 2.1 M | |
| Braidwell Lp | 2024-12-31 | 2.1 M | |
| Aqr Capital Management Llc | 2024-12-31 | 1.9 M | |
| Geode Capital Management, Llc | 2024-12-31 | 1.8 M | |
| Deutsche Bank Ag | 2024-12-31 | 1.8 M | |
| Boxer Capital Llc | 2024-09-30 | 1.7 M | |
| Bank Of America Corp | 2024-12-31 | 1.7 M | |
| Polar Capital Holdings Plc | 2024-12-31 | 1.6 M | |
| Venbio Select Advisor Llc | 2024-12-31 | 12.2 M | |
| Ecor1 Capital, Llc | 2024-12-31 | 11.9 M |
Apellis Pharmaceuticals Historical Income Statement
Apellis Stock Against Markets
Apellis Pharmaceuticals Corporate Management
| James CPA | Corporate VP | Profile | |
| Cedric MD | President, CoFounder | Profile | |
| Adam Townsend | Chief Commercial Officer | Profile | |
| Karen Lewis | Chief Officer | Profile | |
| Nur Nicholson | Chief Officer | Profile |
Already Invested in Apellis Pharmaceuticals?
The danger of trading Apellis Pharmaceuticals is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Apellis Pharmaceuticals is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Apellis Pharmaceuticals. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Apellis Pharmaceuticals is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additional Tools for Apellis Stock Analysis
When running Apellis Pharmaceuticals' price analysis, check to measure Apellis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Apellis Pharmaceuticals is operating at the current time. Most of Apellis Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Apellis Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Apellis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Apellis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.